001 | 132485 | ||
005 | 20240229105018.0 | ||
024 | 7 | _ | |a 10.1093/neuonc/nox141 |2 doi |
024 | 7 | _ | |a pmid:29016845 |2 pmid |
024 | 7 | _ | |a pmc:PMC5786244 |2 pmc |
024 | 7 | _ | |a 1522-8517 |2 ISSN |
024 | 7 | _ | |a 1523-5866 |2 ISSN |
024 | 7 | _ | |a altmetric:32070368 |2 altmetric |
037 | _ | _ | |a DKFZ-2018-00172 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Jones, David |0 P:(DE-He78)551bb92841f634070997aa168d818492 |b 0 |e First author |u dkfz |
245 | _ | _ | |a Pediatric low-grade gliomas: next biologically driven steps. |
260 | _ | _ | |a Oxford |c 2018 |b Oxford Univ. Press |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1659955578_8497 |2 PUB:(DE-HGF) |x Review Article |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a Despite the fact that they are not typically life-threatening, low-grade gliomas (LGGs) remain a significant clinical challenge in pediatric neuro-oncology due to comorbidities associated with these tumors and/or their treatments, and their propensity to multiply recurs. LGGs, in total the most common brain tumors arising in childhood, can often become a chronic problem requiring decades of management. The Second International Consensus Conference on Pediatric Low-Grade Gliomas held in Padua, Italy in 2016 was convened in an attempt to advance the pace of translating biological discoveries on LGGs into meaningful clinical benefit. Topics discussed included: the implications of our growing biological understanding of the genomics underlying these tumors; the assessment of the model systems available; the implications of the molecular and histopathologic differences between adult and pediatric diffuse gliomas; and steps needed to expedite targeted therapy into late-stage clinical trials for newly diagnosed cases. Methods for the diagnostic assessment of alterations in the Ras/mitogen-activated protein kinase pathway, typical for these tumors, were also considered. While the overall tone was positive, with a consensus that progress is being and will continue to be made, the scale of the challenge presented by this complex group of tumors was also acknowledged. The conclusions and recommendations of the meeting panel are provided here as an outline of current thinking and a basis for further discussion. |
536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
700 | 1 | _ | |a Kieran, Mark W |b 1 |
700 | 1 | _ | |a Bouffet, Eric |b 2 |
700 | 1 | _ | |a Alexandrescu, Sanda |b 3 |
700 | 1 | _ | |a Bandopadhayay, Pratiti |b 4 |
700 | 1 | _ | |a Bornhorst, Miriam |b 5 |
700 | 1 | _ | |a Ellison, David |b 6 |
700 | 1 | _ | |a Fangusaro, Jason |b 7 |
700 | 1 | _ | |a Fisher, Michael J |b 8 |
700 | 1 | _ | |a Foreman, Nicholas |b 9 |
700 | 1 | _ | |a Fouladi, Maryam |b 10 |
700 | 1 | _ | |a Hargrave, Darren |b 11 |
700 | 1 | _ | |a Hawkins, Cynthia |b 12 |
700 | 1 | _ | |a Jabado, Nada |b 13 |
700 | 1 | _ | |a Massimino, Maura |b 14 |
700 | 1 | _ | |a Mueller, Sabine |b 15 |
700 | 1 | _ | |a Perilongo, Giorgio |b 16 |
700 | 1 | _ | |a Schouten van Meeteren, Antoinette Y N |b 17 |
700 | 1 | _ | |a Tabori, Uri |b 18 |
700 | 1 | _ | |a Warren, Katherine |b 19 |
700 | 1 | _ | |a Waanders, Angela J |b 20 |
700 | 1 | _ | |a Walker, David |b 21 |
700 | 1 | _ | |a Weiss, William |b 22 |
700 | 1 | _ | |a Witt, Olaf |0 P:(DE-He78)143af26de9d57bf624771616318aaf7c |b 23 |u dkfz |
700 | 1 | _ | |a Wright, Karen |b 24 |
700 | 1 | _ | |a Zhu, Yuan |b 25 |
700 | 1 | _ | |a Bowers, Daniel C |b 26 |
700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 27 |u dkfz |
700 | 1 | _ | |a Packer, Roger J |b 28 |
773 | _ | _ | |a 10.1093/neuonc/nox141 |g Vol. 20, no. 2, p. 160 - 173 |0 PERI:(DE-600)2094060-9 |n 2 |p 160 - 173 |t Neuro-Oncology |v 20 |y 2018 |x 1523-5866 |
909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:132485 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)551bb92841f634070997aa168d818492 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 23 |6 P:(DE-He78)143af26de9d57bf624771616318aaf7c |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
914 | 1 | _ | |y 2018 |
915 | _ | _ | |a Allianz-Lizenz / DFG |0 StatID:(DE-HGF)0400 |2 StatID |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2015 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NEURO-ONCOLOGY : 2015 |
920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)B062-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|